2356 results about "Treatment use" patented technology

Abstract of Disclosure The present invention provides methods and compositions for attenuating expression of a target gene in vivo. In general, the method includes administering RNAi constructs (such as small-interfering RNAs (i.e., siRNAs) that are targeted to particular mRNA sequences, or nucleic acid material that can produce siRNAs in a cell), in an amount sufficient to attenuate expression of a target gene by an RNA interference mechanism, e.g., in a sequence-dependent, PKR-independent manner. In particular, the subject method can be used to alter the growth, survival or differentiation of cells for therapeutic and cosmetic purposes.

Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab), optionally with an albumin-binding peptide (ABP) sequence, are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered antibody-drug conjugates having Formula I: Ab-(L-D)p  I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.

Oxygen defects formed at the boundary between the zinc oxide type oxide semiconductor and the gate insulator are terminated by a surface treatment using sulfur or selenium as an oxygen group element or a compound thereof, the oxygen group element scarcely occurring physical property value change. Sulfur or selenium atoms effectively substitute oxygen defects to prevent occurrence of electron supplemental sites by merely applying a gas phase or liquid phase treatment to an oxide semiconductor or gate insulator with no remarkable change on the manufacturing process. As a result, this can attain the suppression of the threshold potential shift and the leak current in the characteristics of a thin film transistor.

The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anri-ErbB receptor antibody-maytansinoid conjugates.

A relay device relays signals between a single switch unit and each of an ultrasonic surgical device that supplies an ultrasonic signal and an electrosurgical device that supplies a high-frequency signal, the switch unit being used for on / off control of outputs of the ultrasonic surgical device and the electrosurgical device, the ultrasonic surgical device and the electrosurgical device being connected to an ultrasonic / high-frequency treatment instrument capable of performing an ultrasonic treatment using ultrasonic vibration in accordance with the supplied ultrasonic signal and performing a high-frequency treatment in accordance with the supplied high-frequency signal. The relay device includes a switch detection unit for detecting the turn-on / off of the switch unit, a switch element for outputting a switch signal, which is used for on / off control of outputs of the ultrasonic signal and the high-frequency signal, to each of the ultrasonic surgical device and the electrosurgical device in accordance with a detection output of the switch detection unit, and a control unit for performing on / off control of the switch signal of the switch element in accordance with the detection output to control at least one of an output timing and an output mode of each of the ultrasonic signal and the high-frequency signal.

Bispecific antibody derivatives are disclosed which are comprised of a first region which binds to a first antigen and a second region which binds to a second antigen different from the first antigen. The first and second regions of the bispecific antibody are each stabilized by an additional internal disulfide bridge, and connected by a flexible polypeptide linker. The bispecific antibody is devoid of an Fc portion and is encoded as a single chain-sequence.

The present disclosure provides drug-cleavable substrate conjugates that are potent cytotoxins. The disclosure is also directed to compositions containing the drug-cleavable substrate conjugates, and to methods of treatment using them.

The invention relates to stable pharmaceutical or cosmetic foam compositions containing certain active agents, having unique therapeutic properties and methods of treatment using such compositions. The foamable composition includes at least one solvent comprising polyethylene glycol (PEG) or PEG derivative and mixtures thereof, or comprising propylene glycol, wherein the solvent is present at a concentration of about 70% to about 96.5% by weight of the total composition, at least a non-ionic surface-active agent at a concentration of about 0.1% to less than about 10% by weight of the total composition.

Disclosed is a system and method of assessing the efficacy of and predicting response to treatment of neurological or psychological disorders. The preferred embodiment uses at least two surface electrodes to acquire EEG signals from the surface of a patient's body, a processor for computing from the EEG signals various features and indices that are representative of the patient's neurological or psychological state. Pretreatment indices represent a patient's neurological or psychological state and therefore may be used to predict the response to treatment. Changes in these parameters may be used to assess the efficacy of treatment and to modify the treatment to optimize the resultant patient state.

A system is described for removing heat from a subject's subcutaneous lipid-rich regions, such as tissues, organs, cells, and so forth. In various embodiments, the system includes a controller, a computing device, a data acquisition device, a chiller, and one or more applicators. The system can employ these components to receive a selection of a treatment profile and apply the selected treatment using an applicator. The system provides various user interfaces.

The present invention is a method, process and apparatus for selective cleaning, drying, and modifying substrate surfaces and depositing thin films thereon using a dense phase gas solvent and admixtures within a first created supercritical fluid antisolvent. Dense fluids are used in combination with sub-atmospheric, atmospheric and super-atmospheric plasma adjuncts (cold and thermal plasmas) to enhance substrate surface cleaning, modification, precision drying and deposition processes herein. Moreover, conventional wet cleaning agents such as hydrofluoric acid and ammonium fluoride may be used with the present invention to perform substrate pre-treatments prior to precision drying and cleaning treatments described herein. Finally, dense fluid such as solid phase carbon dioxide and argon may be used as a follow-on treatment or in combination with plasmas to further treat a substrate surface.

Monoclonal anti-human CD20 antigen binding antibodies containing human IgG3 constant domains are provided. These antibodies possess effector functions that render them well suited for use in therapeutic methods, especially treatments wherein inhibition of B cell function or B cell number is therapeutically desirable.

The present invention relates to pyrazinoylguanidine compounds represented by formula (I): where at least one of R3 and R4 is a group represented by formula (A): where the other structural groups are defined herein. The present invention also includes a variety of methods of treatment using these sodium channel blockers.

A method of treating a perforator vein comprises applying ultrasound to the perforator vein and occluding the perforator vein with the ultrasound. An apparatus for treating blood vessels comprises an ultrasound emitter, wherein the ultrasound emitter is configured to emit ultrasound at multiple therapeutic ultrasound frequencies during a treatment cycle. The apparatus further comprises an acoustic coupler in sonic communication with the emitter, wherein the acoustic coupler has an acoustic coupling surface configured to contact a patient and facilitate delivery of ultrasound to the patient and wherein the acoustic coupler provides a conduction path for ultrasound from the emitter to the acoustic coupling surface. The apparatus further comprises an acoustic coupler containing a displaceable acoustic coupling material. The apparatus further comprises an acoustic coupler configured to vary the length of the conduction path in accordance with variation in the thickness of the acoustic coupling material disposed between the emitter and the acoustic coupling surface.

Biocompatible materials are propelled at the skin with sufficient velocity to cause desired resurfacing of skin layers to the desired penetration depth. The materials, such as dry ice or water ice, are harmonious with the human body and thus eliminate foreign body reactions. Various materials may be used in combination, including local anesthetics and vasoconstrictors in solid or liquid form. The biocompatible solid or liquid particles are suspended in a cold carrier fluid and propelled through an insulated delivery system to the surface of the skin. The treatment of diseased skin lesions may be accomplished using the present invention as a drug delivery system.

The present invention provides articles of manufacture comprising biocompatible nanostructures comprising significantly increased surface area for, e.g., organ, tissue and / or cell growth, e.g., for bone, tooth, kidney or liver growth, and uses thereof, e.g., for in vitro testing of drugs, chemicals or toxins, or as in vivo implants, including their use in making and using artificial tissues and organs, and related, diagnostic, screening, research and development and therapeutic uses, e.g., as drug delivery devices. The present invention provides biocompatible nanostructures with significantly increased surface area, such as with nanotube and nanopore array on the surface of metallic, ceramic, or polymer materials for enhanced cell and bone growth, for in vitro and in vivo testing, cleansing reaction, implants and therapeutics. The present invention provides optically transparent or translucent cell-culturing substrates. The present invention provides biocompatible and cell-growth-enhancing culture substrates comprising elastically compliant protruding nanostructure substrates coated with Ti, TiO2 or related metal and metal oxide films.

The present disclosure provides drug-cleavable substrate conjugates that are potent cytotoxins. The disclosure is also directed to compositions containing the drug-cleavable substrate conjugates, and to methods of treatment using them.

An improved electrosurgical instrument and method is disclosed for simplifying making incisions and other treatments using electrosurgery. The electrosurgical instrument comprises a body having more than two electrodes with at least two electrodes having alternating current power supplied to them such that they comprise a bipolar alternating current configuration and employ a means other than electrode spacing, composition, or geometry for reducing or preventing accumulation of eschar that would otherwise form a short circuit current path and interfere with obtaining a predetermined surgical effect. In one aspect, such means for reducing or preventing eschar accumulation consists of at least one other electrode having a direct current voltage between it and at least one of the two electrodes forming the alternating current bipolar configuration. In another aspect of the invention two or more pairs of alternating current electrodes comprising bipolar electrodes are powered with alternating current having a nonzero RMS voltage sufficient to at least reduce eschar accumulations on one electrode or induce electrolysis of at least one component of a medium surrounding at least one pair of bipolar electrodes. The electrodes are separated from each other using electrically insulating materials such that electric current does not flow between at least two of the bipolar alternating current electrodes unless they contact at least one other electrically conductive medium, such as patient tissue or a medium comprising at least in part a solid, liquid, gas, or ionized component that allows electric current to flow between electrodes. In the aspect where at least one electrode is powered by direct current the electrodes are configured such that electrical current does not flow between at least one of the bipolar alternating current electrodes and at least one of the direct current electrodes unless one or more media, such as patient tissue or a medium comprising at least in part a solid, liquid, gas, or ionized component that allows electric current to flow between electrodes, are contacting or adjacent to the electrodes having a direct current voltage difference between them. The assembly comprised of the electrodes and the separating insulating materials may also employ one or more means to reduce the current flowing between them that does not produce a desired predetermined surgical effect with one aspect of such means being using an outer insulating coating configured such that one or more portions of at least one of the bipolar alternating current electrodes are insulated while leaving exposed other portions of such insulated electrodes so that they are capable of being in electrical communication with tissue or at least one material in electrical communication with tissue.

An energy control device supplies power to an ultrasonic treatment instrument including an end effector performing treatment using ultrasonic vibration generated by an ultrasonic transducer. The energy control device includes an energy source configured to output the power to the ultrasonic transducer, and an integrated circuit. The integrated circuit is configured to: acquire a resonance frequency of a vibration system including the ultrasonic transducer; calculate an initial feature value relating to the resonance frequency after a start of an output of the power; set a threshold based on the initial feature value; and perform causing the energy source to stop or reduce the output of the power to the ultrasonic transducer based on a relationship between the resonance frequency and the threshold, or notifying the relationship between the resonance frequency and the threshold.

A laser indirect ophthalmoscope (LIO) apparatus for photomedical treatment and / or diagnosis is presented. The LIO apparatus allows multiple spot ophthalmic surgery to be performed in a wider range of patient positions and less intrusively than currently available methods. The LIO apparatus utilizes a separate or integral beam multiplier that generates one or more optical beams via spatial and / or temporal separation, and an optical system that conditions and directs the one or more optical beams to a target to form a pattern. The LIO apparatus includes a headset, and is therefore wearable by the user (e.g., a physician).